How to launch a UK gout telehealth service in 2026: acute flares, urate-lowering therapy, and monitoring

Gout is common, painful and badly managed almost everywhere — most patients bounce between agonising flares and long undertreated gaps. That makes it a genuine telehealth opportunity, because good gout care is mostly structured monitoring and titration, which remote services do well. But it is easy to run as a flare-only painkiller service and miss the point. Here is how to build one that actually lowers urate.

Why gout is a two-part problem

Gout has two distinct clinical jobs, and conflating them is the classic error. The first is the acute flare: intense, self-limiting joint pain that needs fast anti-inflammatory treatment. The second is the underlying cause: chronically raised serum urate that keeps depositing crystals and driving flares until it is brought down.

A flare-only service treats the pain and ignores the disease, leaving patients to flare again and again. A good service does both — settles the flare and, in the right patients, starts and titrates urate-lowering therapy to prevent the next one. The value is in the second part.

Treating the acute flare

Acute flare treatment usually draws on one of three options, chosen by contraindications and comorbidity — prescriber discretion applies:

• NSAIDs — effective but cautioned in renal impairment, cardiovascular disease and GI risk.
• Colchicine — useful where NSAIDs are unsuitable; dose matters, as it is toxic in overdose and interacts with several drugs.
• Corticosteroids — oral steroids are an option where both NSAIDs and colchicine are inappropriate.

The assessment has to weigh kidney function, cardiovascular and GI risk and current medicines. This is not a one-size prescription; it is a clinical choice that a proper remote assessment supports.

Urate-lowering therapy and treat-to-target

The disease-modifying half is urate-lowering therapy (ULT), most commonly allopurinol, with febuxostat as an alternative. The principle, set out in guidance such as NICE NG219 and the BSR, is treat-to-target: start low, titrate up gradually, and aim for a serum urate below a defined target so crystals dissolve and flares stop.

Crucially, ULT is started and adjusted against blood results, not symptoms, and flares can temporarily increase when it begins, so cover and counselling matter. A service that puts patients on a fixed allopurinol dose and never re-checks urate is not doing treat-to-target — it is just dispensing a tablet.

The role of blood tests

Blood tests are the spine of gout management, just as with thyroid care. Serum urate guides whether and how far to titrate ULT, and renal function shapes drug choice and dosing. A remote service needs a reliable route to obtain these — home kits or partner phlebotomy — and to act on the results.

Titrating allopurinol without current urate and renal results is prescribing blind. Build the monitoring loop as core infrastructure, keep results in the record, and let a flagged result drive the next dose decision. Our guide to records and retention covers keeping that defensible.

Safety and referral limits

Some cases sit outside a routine remote pathway. Diagnostic uncertainty — a hot, swollen joint could be septic arthritis, an emergency — needs urgent assessment, not a gout script. Significant renal impairment, recurrent tophaceous disease, suspected drug reactions, and patients not responding to treatment warrant closer or specialist care.

Allopurinol also carries a small risk of serious hypersensitivity reactions, so counselling and clear safety-netting about stopping and seeking help are essential. Clinicians need thresholds for escalation and should document them. A service that treats every painful joint as gout will eventually miss a joint infection.

A service that treats every painful joint as gout will eventually miss a joint infection. A hot, swollen joint could be septic arthritis — an emergency — and diagnostic uncertainty leaves the remote pathway for urgent assessment.

Building the service

Operationally, gout combines a fast acute pathway with a slow monitoring one, so the service has to do both: quick flare treatment and a patient, structured titration-and-review cadence with blood tests. Wrap it in standard procedures so the same approach applies each time — our guide to clinical SOPs covers that. The testing loop is the distinctive build cost, layered on the usual regulated spine of identity, prescriber governance and dispensing.

As ever, that regulated layer is the slow, expensive part — see our launch checklist for the sequence and where monitoring fits.

How PExpo supports a gout launch

PExpo provides the regulated layer — registered dispensing, prescriber governance, pharmacovigilance and the patient record that ties urate results to prescriptions — so a brand can run a treat-to-target gout service on a compliant base rather than assembling the loop from scratch.

You bring the brand and the patient relationship; the titration governance and monitoring continuity sit on infrastructure built to support them. See our brand model and pricing.

Gout rewards operators who build for treat-to-target rather than flare-only supply: settle the acute attack safely, start and titrate urate-lowering therapy against blood results, monitor to target, and refer the uncertain or complicated case. See our launch checklist and brand model for the operational detail.

Frequently asked questions